Research Topics
| D J WallaceSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Management of lupus erythematosus: recent insightsDaniel J Wallace
Cedars-Sinai/UCLA School of Medicine, Los Angeles, California 90048, USA
Curr Opin Rheumatol 14:212-9. 2002..Twelve biologic agents have been studied in lupus since 1999, with only LJP-394 showing clear-cut, convincing efficacy...- Fibromyalgia: the gastrointestinal linkDaniel J Wallace
Cedars Sinai UCLA School of Medicine, 8737 Beverly Blvd, Suite 203, Los Angeles, CA 90048, USA
Curr Pain Headache Rep 8:364-8. 2004..Of those patients with FM, 30% to 70% have concurrent IBS. Small intestinal bacterial overgrowth is associated with hyperalgesia and IBS-like complaints, is common in FM, and responds transiently to antimicrobial therapy... - Hypothesis: bipolar illness with complaints of chronic musculoskeletal pain is a form of pseudofibromyalgiaDaniel J Wallace
Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Semin Arthritis Rheum 37:256-9. 2008.... 
Ten developments in the use of biologicals for systemic lupus erythematosusDaniel J Wallace
Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Curr Rheumatol Rep 15:337. 2013..Most of the promising approaches involve B cell depletion or modulation. Post-approval experience with belimumab is critically reviewed...- Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosusDj Wallace
1Cedars Sinai Medical Center David Geffen School of Medicine at UCLA, Los Angeles, California, USA
Lupus 22:144-54. 2013..ClinicalTrials.gov identifiers: LBSL02: NCT00071487; BLISS-52: NCT00424476; BLISS-76: NCT00410384... - New insights into mechanisms of therapeutic effects of antimalarial agents in SLEDaniel J Wallace
Division of Rheumatology, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Becker B 131, Los Angeles, CA 90048, USA
Nat Rev Rheumatol 8:522-33. 2012..Antimalarial agents have unique disease-modifying properties in SLE and newer iterations of this class of anti-inflammatory agents will have a profound effect upon the treatment of autoimmune disease... 
The utility of MRI in predicting radiographic erosions in the metatarsophalangeal joints of the rheumatoid foot: a prospective longitudinal cohort studyMatthew L Mundwiler
North Suburban Rheumatologists, Des Plaines, IL 60016, USA
Arthritis Res Ther 11:R94. 2009..Similar analyses were performed for bone marrow edema, predicting a subsequent MRI erosion. Descriptive results of other lesions are reported...- Improving the prognosis of SLE without prescribing lupus drugs and the primary care paradoxD J Wallace
Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Lupus 17:91-2. 2008..Rheumatologists need to take the responsibility to ensure that their lupus patients have optimal primary care access which includes a working relationship with them... - What's new in the management of lupus since 2000?Daniel J Wallace
Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
J Clin Rheumatol 12:307-13. 2006 - The physician Hans Reiter as prisoner of war in Nuremberg: a contextual review of his interrogations (1945-1947)Daniel J Wallace
Division of Rheumatology, Department of Medicine, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA
Semin Arthritis Rheum 32:208-30. 2003..Reactive arthritis is often termed Reiter's syndrome, after Hans Reiter, who was incarcerated at Nuremberg... - Is there a role for cytokine based therapies in fibromyalgiaDaniel J Wallace
Cedars Sinai David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Curr Pharm Des 12:17-22. 2006..A review of the fibromyalgia literature and related studies suggest that IL-1, IL-6 and IL-8 are dysregulated in the syndrome. Therapies directed against these cytokines may be of potential importance in the management of fibromyalgia... - Quality-of-life, legal-financial, and disability issues in fibromyalgiaD J Wallace
Department of Medicine Division of Rheumatology, Cedars Sinai Medical Center UCLA School of Medicine, 8737 Beverly Building, Los Angeles, CA 90048, USA
Curr Pain Headache Rep 5:313-9. 2001..The principal legal issues associated with the syndrome are: Does fibromyalgia exist? Can it be caused by or flared by stress or trauma? Does disability apply to fibromyalgia and if so, how? These issues are critically reviewed... - LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosusD J Wallace
Department of Medicine, Division of Rheumatology, Cedars Sinai UCLA School of Medicine, Los Angeles, USA
Lupus 13:323-7. 2004..LJP 394 is a promising induction and/or maintenance therapy for lupus patients with elevated anti-DNA and active disease... - Clinical and pharmacological experience with LJP-394D J Wallace
Clinical Professor of Medicine, Cedars Sinai University of California Los Angeles, 8737 Beverly Blvd, Suite 203, Los Angeles, CA 90048, USA
Expert Opin Investig Drugs 10:111-7. 2001..A definitive trial is in progress. LJP-394 appears to be free of serious adverse reactions. Though promising, the role of LJP-394 in patients with active, organ-threatening lupus is still not known... - Apheresis for lupus erythematosus: state of the artD J Wallace
Cedars Sinai UCLA School of Medicine, Los Angeles, CA 90048, USA
Lupus 10:193-6. 2001..It may be potentially useful in the antiphospholipid syndrome or mothers or children at risk for congenital heart block. Refinements in apheresis technology may expand the indications for PP... - Advances in drug therapy for systemic lupus erythematosusDaniel J Wallace
Division of Rheumatology, Cedars Sinai Medical Center, 8737 Beverly Blvd, Suite 302, West Hollywood, CA 90048, USA
BMC Med 8:77. 2010..This minireview highlights the latest therapies under investigation in SLE and gives an overview of the pathways that are specifically being targeted... - How Prosorba apheresis came to be used for rheumatoid arthritis: a personal historical perspectiveD J Wallace
Cedars Sinai UCLA Medical Center, Los Angeles, California, USA
Ther Apher 5:76-8. 2001..In this article, I review how membrane methodologies evolved with regard to the management of the disorder through a focused review of rarely cited key references and personal experience... - The Patient Reported Outcomes in Lupus (PATROL) study: role of depression in health-related quality of life in a Southern California lupus cohortI Moldovan
Loma Linda University, California, USA
Lupus 20:1285-92. 2011..0001). Conclusion: Depression, and not disease activity, appears to have a major influence on quality of life in both Hispanic and Caucasian patients in this lupus cohort... - Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosusB P Tsao
University of California, Los Angeles, USA
J Clin Invest 99:725-31. 1997..01). We concluded that this candidate 1q41-q42 region probably contains a susceptibility gene(s) that confers risk for SLE in multiple ethnic groups... - Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMCM Linker-Israeli
Department of Medicine, The Cedars Sinai Research Institute and UCLA, Los Angeles, California 90048, USA
Clin Immunol 99:82-93. 2001..These data suggest that 1,25 D(3) compounds can offer novel approaches to the clinical management of SLE... - Posterior reversible encephalopathy syndrome: another manifestation of CNS SLE?M L Ishimori
Division of Rheumatology, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Lupus 16:436-43. 2007..The therapeutic implications for separating PRES from stroke or cerebritis are important. We propose that PRES should be considered in the differential diagnosis in SLE patients with new-onset neurologic signs and symptoms... - Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 yearsJ D Posalski
Cedars Sinai Medical Center, Los Angeles, CA, USA
Lupus 18:516-21. 2009..When evaluating organ system subsets separately, MMF improved disease activity in the first year, but had little effect in preventing new organ-specific flares, with most flares taking place in second and third year of treatment... - Review: Male systemic lupus erythematosus: a review of sex disparities in this diseaseL J Lu
Cedars Sinai Medical Center, Los Angeles, California 90048, USA
Lupus 19:119-29. 2010..This review discusses these findings and sex disparities in SLE that appear to be especially noteworthy and pertinent to our understanding of male SLE... - Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosusElizabeth R Volkmann
David Geffen School of Medicine, University of California, Los Angeles, CA 90095 1670, USA
Arthritis Care Res (Hoboken) 62:258-65. 2010..To investigate the association between physical activity, functional activity of high-density lipoprotein (HDL), and subclinical cardiovascular disease in patients with systemic lupus erythematosus (SLE)... - Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritisMaureen McMahon
University of California at Los Angeles David Geffen School of Medicine, Los Angeles, CA 90095, USA
Arthritis Rheum 54:2541-9. 2006..This study was undertaken to determine whether patients with SLE, who have chronic inflammation that causes oxidative damage, have more proinflammatory HDL and higher levels of ox-LDL, thus predisposing them to atherosclerosis... - Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosusMaureen McMahon
David Geffen School of Medicine, UCLA Medical Center, University of California, Los Angeles, CA 90095, USA
Arthritis Rheum 60:2428-37. 2009..The aim of this study was to determine whether dysfunctional proinflammatory HDL (piHDL) is associated with subclinical atherosclerosis in SLE... - Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite studyDaniel E Furst
Division of Rheumatology, Department of Medicine, University of California Los Angeles, CA 90095 1670, USA
Ann Rheum Dis 66:893-9. 2007..To incorporate a new trial design to examine clinical response, cytokine expression and joint imaging in patients with rheumatoid arthritis (RA) switching from etanercept to infliximab treatment... - Familiality and co-occurrence of clinical features of systemic lupus erythematosusBetty P Tsao
Division of Rheumatology, Department of Medicine, Rehabilitation Center, Room 32 59, University of California Los Angeles School of Medicine, 1000 Veteran Avenue, Los Angeles, CA 90095 1670, USA
Arthritis Rheum 46:2678-85. 2002..To evaluate familiality of 15 clinical and laboratory features in systemic lupus erythematosus (SLE)-affected sibpairs, and to estimate correlations with the age at SLE diagnosis in affected sibpairs and parent-offspring pairs... - Linkage and interaction of loci on 1q23 and 16q12 may contribute to susceptibility to systemic lupus erythematosusBetty P Tsao
Department of Medicine, Rehabilitation Center, Room 32 59, 1000 Veteran Avenue, UCLA School of Medicine, Los Angeles, CA 90095 1670, USA
Arthritis Rheum 46:2928-36. 2002.... - Systemic lupus erythematosusDaniel J Wallace
Clinical Professor of Medicine, UCLA School of Medicine, Los Angeles, CA 90048, USA
Drugs Today (Barc) 38:259-63. 2002.... - Benefits of leflunomide in systemic lupus erythematosus: a pilot observational studyC F Remer
Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA
Lupus 10:480-3. 2001..Blood pressure was unchanged. Leflunomide was efficacious and safe in this cohort of SLE patients after 2-3 months of therapy. Placebo-controlled trials of longer duration are indicated... - Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot studyD J Wallace
Department of Medicine/Division of Rheumatology, Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CA, USA
Rheumatology (Oxford) 40:743-9. 2001..Because IL-8 promotes sympathetic pain and IL-6 induces hyperalgesia, fatigue and depression, it is hypothesized that they may play a role in modulating FM symptoms... - Telomere shortening and decreased replicative potential, contrasted by continued proliferation of telomerase-positive CD8+CD28(lo) T cells in patients with systemic lupus erythematosusM Honda
Department of Medicine, Cedars-Sinai Research Institute and the University of California at Los Angeles, Los Angeles, CA 90048, USA
Clin Immunol 99:211-221. 2001..5 TAU in CD8+CD28(hi) cells and 0.3 TAU in bulk PBMC; P = 0.05]. These T cell anomalies could be due to chronic in vivo stimulation of the immune system and may contribute to the immune dysregulation found in SLE... - Association of a common complement receptor 2 haplotype with increased risk of systemic lupus erythematosusHui Wu
Division of Rheumatology, University of California Los Angeles, 1000 Veteran Avenue, Los Angeles, CA 90095, USA
Proc Natl Acad Sci U S A 104:3961-6. 2007..Our findings reveal that CR2 is a likely susceptibility gene for human lupus at 1q32.2, extending previous studies suggesting that CR2 participates in the pathogenesis of systemic lupus erythematosus... - Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placeboV Strand
Division of Immunology, Stanford University, Palo Alto, CA, USA
Lupus 12:677-86. 2003..Differences between treatment groups in RE and SF domains are clinically important and were replicated irrespective of the protocol population analysed... - The lowest surviving birth weight reported in a systemic lupus erythematosus patient: a review of the literatureJ Spiegel
Division of Rheumatology, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Lupus 16:52-5. 2007..This report represents the lowest birth weight pregnancy survival in a lupus patient and the first case of a survival in the second trimester with preeclampsia and HELLP syndrome... - Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivityA Ippolito
Division of Rheumatology, Johns Hopkins University School of Medicine, 1830 E Monument Street, Baltimore, MD 21205, USA
Lupus 20:250-5. 2011..Variation in the results for complement, however, is more likely to be explained by response to treatment. These findings deserve consideration in the context of diagnosis and enrolment in clinical trials... - High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosusN Firooz
Cedars Sinai Medical Center, Los Angeles, California, USA
Lupus 20:588-97. 2011..Elevated hsCRP levels can be used as a predictor of active infection in SLE patients with a high specificity. We review the relationship between IL-6 and hsCRP production in lupus patients... - Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex familiesR Shai
Division of Rheumatology, Department of Medicine, University of Southern California School of Medicine, 2011 Zonal Avenue, HMR 711, Los Angeles, CA 90033, USA
Hum Mol Genet 8:639-44. 1999.... - Gastrointestinal manifestations of systemic lupus erythematosusD S Hallegua
Division of Rheumatology, Cedars Sinai Medical Center UCLA School of Medicine Los Angeles, California, USA
Curr Opin Rheumatol 12:379-85. 2000..In patients with abdominal pain and active SLE, it is critical to diagnose vasculitis or thrombosis with appropriate scanning and institute early immunosuppressive or surgical treatment... - Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosusJ G Hanly
Department of Medicine, Division of Rheumatology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada
Ann Rheum Dis 70:1726-32. 2011..This study examined a disease inception cohort of 1047 SLE patients to determine which autoantibodies at enrolment predicted subsequent neuropsychiatric events... - Novel therapies in the treatment of systemic lupus erythematosusC R Dequet
Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Curr Opin Investig Drugs 2:1045-53. 2001..In our opinion, leflunomide and LJP-394 are the most promising therapies currently, under study... - PARP alleles within the linked chromosomal region are associated with systemic lupus erythematosusB P Tsao
Division of Rheumatology, Department of Medicine, University of California Los Angeles School of Medicine, Los Angeles, California 90095 1670
J Clin Invest 103:1135-40. 1999..004). Similar TDT analyses of TGFB2 and HLX1 polymorphisms yielded no evidence for association with SLE. These results suggest that PARP may be (or is close to) the susceptibility gene within the chromosome 1q41-q42 region linked to SLE... - Depression predicts self-reported disease activity in systemic lupus erythematosusF N Carr
California School of Professional Psychology, Alliant International University, Los Angeles, California, USA
Lupus 20:80-4. 2011..Longitudinally, depression alone predicted self-reported disease activity. These data suggest that depression may play a significant role in the health status of SLE patients and serve as an important target for clinical intervention... - Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosusAnca D Askanase
Department of Medicine, Hospital for Joint Diseases, Division of Rheumatology, New York University School of Medicine, 560 First Avenue, TCH 407, New York, NY 10016, USA
J Rheumatol 36:89-95. 2009..Our objective was to evaluate whether drug escalation based on metabolite levels improves efficacy and maintains safety in patients with systemic lupus erythematosus (SLE)... - A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosusDaniel J Wallace
Cedars Sinai Medical Center, University of California, Los Angeles, USA
Arthritis Rheum 61:1168-78. 2009..To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combination with standard of care therapy (SOC) in patients with active systemic lupus erythematosus (SLE)... - The management of fibromyalgia-associated syndromesDavid S Silver
Division of Rheumatology, Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA 90048, USA
Rheum Dis Clin North Am 28:405-17. 2002..The successful treatment of fibromyalgia-associated syndromes improves the symptoms, quality of life, and prognosis of fibromyalgia... - Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid diseaseHui Wu
David Geffen School of Medicine, University of California, Los Angeles, 90095, USA
Arthritis Rheum 52:2396-402. 2005..We performed family-based association studies of this polymorphism in 4 independent cohorts containing SLE patients and their parents and/or other family members... - Development and validation of a preference weight multiattribute health outcome measure for rheumatoid arthritisChiun-Fang Chiou
Amgen, Inc, Thousand Oaks, California, USA
J Rheumatol 33:2409-11. 2006..All validity test results were statistically significant. CONCLUSION: Our results reveal that the new measures are reliable and valid in assessing health states and associated preference weights of patients with RA... - Eligibility, utilization, and costs in a California Medicaid lupus populationMichael B Nichol
University of Southern California, Los Angeles, California 90033, USA
Arthritis Rheum 51:996-1003. 2004..To investigate whether ethnicity was associated with differences in Medicaid eligibility, health care utilization, and direct medical costs in a systemic lupus erythematosus (SLE) population... - Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndromeCai Sheng Lu
University of California, Los Angeles, CA 90095, USA
Arthritis Rheum 52:4018-27. 2005..To test the hypotheses that some plasmin-reactive anticardiolipin antibodies (aCL) may bind to tissue plasminogen activator (tPA) and that some of the tPA-reactive aCL may inhibit tPA activity... - Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritisMichael H Weisman
Cedars Sinai Medical Center, Los Angeles, California, USA
Arthritis Rheum 54:607-12. 2006..This study investigated whether risk genotypes for folate-dependent enzymes are associated with the toxicity of MTX in patients with rheumatoid arthritis (RA)... - Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLES A Lander
Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA
Lupus 11:340-7. 2002..These results suggest that patients with SLE can be safely and effectively treated with celecoxib; however, further studies are needed to assess the effectiveness and safety of all NSAIDs in SLE... - Risk:benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosusArash A Horizon
Cedars Sinai UCLA School of Medicine, Los Angeles, CA 90048, USA
Expert Opin Drug Saf 3:273-8. 2004..Nevertheless, NSAIDs can safely be prescribed to most lupus patients provided that their administration is re-evaluated on a regular basis and the patient is closely monitored... - Clinical validation of the watershed sign as a marker for neuropsychiatric systemic lupus erythematosusCatherine B Driver
Cedars Sinai Medical Center, Los Angeles, California, USA
Arthritis Rheum 59:332-7. 2008.... - Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritisEllen M Ginzler
Division of Rheumatology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
N Engl J Med 353:2219-28. 2005..Since anecdotal series and small, prospective, controlled trials suggest that mycophenolate mofetil may be effective for treating lupus nephritis, larger trials are desirable... - Lupus registries: evolution and challengesLiang Jing Lu
Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
Semin Arthritis Rheum 39:224-45. 2010.... - Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcomeErnest R Vina
Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
Semin Arthritis Rheum 35:175-84. 2005.... - Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)Christian E Antoni
Clinical Immunology, Schering Plough Corporation, Kenilworth, New Jersey 07033 0530, USA
J Rheumatol 35:869-76. 2008..To investigate longterm efficacy/safety of infliximab over 2 years in patients with active psoriatic arthritis (PsA)... - Measuring preference weights for American college of rheumatology response criteria for patients with rheumatoid arthritisChiun-Fang Chiou
Cerner Health Insights, Beverly Hills, California 90212, USA
J Rheumatol 32:2326-9. 2005..CONCLUSION: VAS weights for 16 ACR response health states of patients with RA were derived. These weights could be used for cost-utility analyses of interventions for patients with RA... - Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trialMario H Cardiel
Hospital General Dr Miguel Silva, Morelia, Michoacan, Mexico
Arthritis Rheum 58:2470-80. 2008.... - Retraction of the suggestion to use the term "Reiter's syndrome" sixty-five years later: the legacy of Reiter, a war criminal, should not be eponymic honor but rather condemnationRichard S Panush
Arthritis Rheum 56:693-4. 2007 - The use of etanercept and other tumor necrosis factor-alpha blockers in infertility: it's time to get seriousDaniel J Wallace
J Rheumatol 30:1897-9. 2003 - To fibromyalgia nihilists: stop pontificating and test your hypothesisDaniel J Wallace
J Rheumatol 31:632. 2004 - Whiplash: a case of regretting being responsible for naming a conditionDaniel J Wallace
J Clin Rheumatol 11:61. 2005 - Rapid prevention of vertebral fractures associated with osteoporosisDaniel J Wallace
Cedars-Sinai Medical Center/David Geffen School of Medicine at UCLA, Los Angeles, Calif. 90047, USA
Orthopedics 28:291-8. 2005..Rapid reduction in fracture risk is achievable with the potent therapeutic agents available... - Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)Christian E Antoni
Friedrich Alexander University, Erlangen Nuremberg, Germany
Arthritis Rheum 52:1227-36. 2005..To investigate the efficacy and tolerability of infliximab therapy for the articular and dermatologic manifestations of active psoriatic arthritis (PsA)... - New European recommendations (European League Against Rheumatism 2008) for the management of lupus erythematosus: American perspectiveDaniel J Wallace
Pol Arch Med Wewn 118:402-3. 2008 - New therapies in systemic lupus erythematosusMarilyn A Solsky
Best Pract Res Clin Rheumatol 16:293-312. 2002..A handful of biologicals have been studied in clinical trials. After two decades without new options for lupus patients practitioners now have a full menu of improved therapeutic options... - Pyridostigmine for fibromyalgia: comment on the article by Paiva and a historical vignetteDaniel J Wallace
Arthritis Rheum 48:277-8. 2003 - Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response indexMichelle Petri
Department of Rheumatology, Johns Hopkins University, Baltimore, Maryland 21205, USA
Arthritis Rheum 58:1784-8. 2008..To develop a measure of renal activity in systemic lupus erythematosus and use it to develop a renal response index... - Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal responseMichelle Petri
Department of Rheumatology, Johns Hopkins University, Baltimore, Maryland 21205, USA
Arthritis Rheum 58:1789-95. 2008..To assess the degree to which physicians agree with each other and with ratings obtained with 3 existing responder indices, in rating the response to treatment of lupus nephritis... - Additional components to measuring fatigue in patients with systemic lupus erythematosus: comment on the article by the Ad Hoc Committee on systemic lupus erythematosus response criteria for fatigueDaniel J Wallace
Arthritis Rheum 59:1049; author reply 1049-50. 2008